Analyse post hoc de patients atteints de polyarthrite rhumatoïde en rémission clinique dans deux essais du peficitinib de phase 3 au Japon (RAJ3 et RAJ4)
Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059
Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.